Intelligent Biopharma

The pace and scale of medical and scientific innovation is transforming the biopharma industry. The need for better patient engagement and experience is spurring new business models. AI is rising across biopharma.

While drug discovery has led to many life-saving and life-enhancing clinical treatments, it is also a long, expensive and often unsuccessful process, with many areas of unmet need. AI-enabled solutions are transforming the process and enabling the development of more precise targeted treatments. This is shifting health care towards a future where medicine is more personalised, predictive, preventative and participatory.

With the traditional clinical trial model proving to be a slow and expensive process, biopharma companies are starting to explore the use of AI technologies to optimise the area. Implemented effectively, AI may be able to improve trial design, analysis of results and real-world evidence, and automate time-consuming processes. The availability of rich data sets and AI-driven analytics could also result in the development of highly effective personalised therapies without the need for large-scale clinical trials.

AI technologies have the potential to transform manufacturing and supply chain management by allowing real-time, end-to-end visibility of workflows. Data-driven processes can support better planning, inventory management, demand forecasting, logistics optimisation, workforce planning and procurement. Use of AI, including dynamic digital supply networks using blockchain and robotic process automation, can allow greater product visibility and enable biopharma companies to meet the demands of next generation products such as cell and gene therapies which require a new level of large-scale precision.

End-to-end visibility across commercialisation could have significant benefits to biopharma companies. Using AI technologies can help companies better coordinate product launches, improve patient engagement, help with physician decision support and marketing operations, and predict market access and pricing decisions.

Post launch, biopharma companies may need interoperable health data to track and engage with patients remotely, an area that many biopharma companies and start-ups are targeting. AI-enabled patient support programmes could transform biopharma's relationship with customers, improve enrolment, adherence and retention, and deliver a better overall patient outcome.

Immerse yourself in the benefits of greater connectivity

Utilise evidence as a critical asset in personalised care

Create new digital ecosystems to shape the future of health